4,4,5,5-Tetramethyl-2-(4-(6-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hex-1-en-2-yl)phenyl)-1,3,2-dioxaborolane

Catalog No. :
ACDRNF865
CAS No. :
2657720-70-0
Molecular Formula :
C30H42B2O4
Molecular Weight :
488.29

IUPAC Name:4,4,5,5-tetramethyl-2-(4-(6-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hex-1-en-2-yl)phenyl)-1,3,2-dioxaborolane

4,4,5,5-Tetramethyl-2-(4-(6-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hex-1-en-2-yl)phenyl)-1,3,2-dioxaborolane structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4,4,5,5-Tetramethyl-2-(4-(6-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hex-1-en-2-yl)phenyl)-1,3,2-dioxaborolane
IUPAC Name4,4,5,5-tetramethyl-2-(4-(6-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hex-1-en-2-yl)phenyl)-1,3,2-dioxaborolane
Molecular FormulaC30H42B2O4
Molecular Weight488.29
SMILESC=C(CC(CCC1=CC=CC=C1)B1OC(C)(C)C(C)(C)O1)C1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1
InChI KeyAEZXCXUXDQYWNM-UHFFFAOYSA-N
Synonym4,4,5,5-tetramethyl-2-(4-(6-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hex-1-en-2-yl)phenyl)-1,3,2-dioxaborolane
CAS No.2657720-70-0

Synthetic Route by SureRoute

1. ACDRNF865 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  4. Then
  5. ACDRNF865 route product structure diagram
    ACDRNF8652657720-70-0
Inquiry

2. ACDRNF865 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACHPYN347 route compound structure diagram
    ACHPYN34768716-49-4 In Stock
  4. Then
  5. ACDRNF865 route product structure diagram
    ACDRNF8652657720-70-0
Inquiry

Comments (0)